<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933526</url>
  </required_header>
  <id_info>
    <org_study_id>20210609</org_study_id>
    <nct_id>NCT04933526</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients</brief_title>
  <official_title>The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in Patients With Chronic Myeloid Leukemia in Chronic Phase: an Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of switching to flumatinib&#xD;
      versus dasatinib after imatinib-related low-grade adverse events in patients with chronic&#xD;
      myeloid leukemia in chronic phase (CML-CP) in China. This is a post-marketing,&#xD;
      interventional, double-arm, prospective, open-label, randomized controlled study in CML-CP&#xD;
      patients in China. Patients will be recruited consecutively from the study sites during the&#xD;
      enrollment period. The enrolled patients will be given flumatinib or dasatinib under the&#xD;
      conditions of informed consent and frequent monitoring according to the clinical guideline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of (CTCAE grading scale) of imatinib related chronic low grade non hematologic Adverse Event after switch to treatment with flumatinib or dasatinib at 3 months.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of a Major Molecular Response (MMR) after the switch to flumatinib or dasatinibin the therapy.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to optimal imatinib-related adverse event improvement.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Chronic Myeloid Leukemia in Chronic Phase</condition>
  <arm_group>
    <arm_group_label>Flumatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600mg QD orally form 1 to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100mg QD orally form 1 to 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumatinib</intervention_name>
    <description>Flumatinib 600mg QD orally form 1 to 12 months</description>
    <arm_group_label>Flumatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100mg QD orally form 1 to 12 months</description>
    <arm_group_label>Dasatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years;&#xD;
&#xD;
          -  Diagnosis of CML-CP with Ph+;&#xD;
&#xD;
          -  ECOG 0, 1, or 2;&#xD;
&#xD;
          -  Patients with imatinib-related Low-grade Adverse Events for more than 12 months and AE&#xD;
             lasting for at least 2 months, or relapsed at least 3 times in the past 12 months;&#xD;
&#xD;
          -  Ability to provide written informed consent prior to any study related screening&#xD;
             procedures being done&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously documented T315I mutation;&#xD;
&#xD;
          -  Previous treatment with any other tyrosine kinase inhibitor except for imatinib;&#xD;
&#xD;
          -  Prior accelerated phase or blast phase CML;&#xD;
&#xD;
          -  Loss of CHR or cytogenetic response&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Du</last_name>
    <phone>075583366388</phone>
    <email>duxingz@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukemia in Chronic Phase</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Flumatinib</keyword>
  <keyword>Dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>HH-GV-678</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

